AbbVie (ABBV)
Health Care · Biopharmaceuticals · NYSE
A global biopharmaceutical leader focused on developing innovative, specialized therapies for immunology, oncology, neuroscience, and aesthetic medicine.
What AbbVie does
AbbVie is a research-based global biopharmaceutical company that develops and markets therapies for complex and serious diseases. Its product portfolio spans key therapeutic areas including immunology, oncology, neuroscience, eye care, and aesthetics. The company focuses on discovering and delivering innovative medicines that address significant unmet medical needs.
Themes: immunology, oncology, neuroscience, medical aesthetics, biologics discovery
Fundamentals
- Price$264.96 as of 2026-08-21 close
- Market cap$468.2B as of 2026-08-21
- 1-year return+26.5% 2025-08-21 close $209.50 → 2026-08-21 close $264.96
- P/E70.24 as of 2026-08-24
- Net margin+9.8% as of 2026-08-24
- Gross margin+72.8% as of 2026-08-24
- ROE+95.6% as of 2026-08-24
- Debt / equity49.22 as of 2026-08-24
- Revenue growth (YoY)+10.4% as of 2026-08-24
- Revenue CAGR (3y)+1.8% SEC XBRL
- Beta0.22 as of 2026-08-24
- Last reported earnings2026-07-31 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +4.5%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How ABBV compares in its sector
- price-to-earnings ratiotop 25% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldtop 10% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ABBV is not currently in any published Top 10 list. Its scores are below.
Long-term score
55.8 #297 of 987 scored · #16 of 57 in Health Care
Profitability 85th (return on equity 95.6%, operating margin 26.2%) and long-term trend 72nd (it is at or near its highest point of the past year); weakest is valuation (8th, price to earnings 74.4 (within its sector)).
Short-term score
49.4 #825 of 1,704 scored · #144 of 240 in Health Care
Volume and participation 73rd: trading volume is about normal versus its 30-day average; catalysts 69th: the analyst consensus rating has improved toward "buy" since the prior reading; weakest is setup 31st: over the past year its closes ranged, and it has retraced essentially none of its move over the past year — 1% of it. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Exceeded at least one reported measure. In FY2025, ABBV's dividend exceeded at least one reported measure of what it earned or generated (earnings payout 276%, free-cash-flow payout 65%). A payout above 100% in one year is not necessarily unsustainable, but it is not fully covered by that measure.
- Earnings payout276% dividends / net income
- Free-cash-flow payout65% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How AbbVie looks technically
AbbVie (ABBV) is trading 17.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 31 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago. It is 0.9% below its all-time high.
Trend
7
| Distance from the 200-day | it is trading 17.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +17.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $247.99 | $247.99 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $226.46 | $226.46 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 31 trading days ago — a "golden cross", a bullish long-term signal | 31 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) | 23.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30) | 64.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($241.20 to $266.92) — its "stochastic" reading is 92 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 92.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $267.47 | $267.47 |
|---|---|---|
| From the 52-week high | it is 0.9% below its 52-week high (its highest price of the past year) | -0.9% |
| Above the 52-week low | it is 38.7% above its 52-week low (its lowest price of the past year) | +38.7% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.9% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $267.47 (set on 2026-07-29) | $267.47 |
| Given back of the 52-week move | over the past year its closes ranged ($197.38 to $265.97), and it has given back essentially none of its rise from last year’s low — 1% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $221.39 to $223.58. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 1.5% |
| From the all-time high | it is 0.9% below its all-time high | -0.9% |
| Nearest price level | it is trading 1.4% above a support level at $261.24 — a price it turned at twice since 2026-07-02, most recently on 2026-07-17. Since 2024-08-21 it has 14 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.4% |
| All-time low | its lowest closing price on record is $32.51 (set on 2012-12-17) | $32.51 |
| Above the all-time low | it is 715.0% above its all-time low | +715.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 74% of it) | 74th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $6.15 between its high and its low — about 2.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $6.15 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $238.65 and $267.94 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $238.65 – $253.29 – $267.94 |
| Typical daily range (% of price) | its price moves about 2.3% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.3% |
| Stretch from the 200-day average | it is trading 6.3 daily ranges above its 200-day average price (17.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.04× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.1% since the prior reading | +0.1% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.4% |
|---|---|---|
| Gap filled | a 2.3% gap up opened on 2026-07-28 has been "filled" 16 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 16 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 1.1 percentage points (the stock gained 3.5% while the market gained 2.3%) | +1.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 20.4 percentage points (the stock gained 23.5% while the market gained 3.1%) | +20.4% |
| vs market, 6 months | over the past 6 months this stock beat the market by 6.8 percentage points (the stock gained 17.9% while the market gained 11.1%) | +6.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 6.0 percentage points (the stock gained 26.5% while the market gained 20.5%) | +6.0% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 8.0% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 7.1% of the share price. | +8.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 17% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $227.10 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +16.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-07-06 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $252.98 — a volume-weighted average of daily closes over 35 sessions, not a true tick-by-tick VWAP. | +4.7% |
Price levels it has turned at before
ABBV last closed at $264.96 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $261.24 | Support | 1.4% below the last close | turned there twice · 2026-07-02 to 2026-07-17 |
| $243.03 | Support | 8.3% below the last close | turned there three times · 2025-10-01 to 2026-08-06 |
| $237.17 | Support | 10.5% below the last close | turned there four times · 2025-11-13 to 2026-03-04 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Near the 52-week high · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · Near the all-time high · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · all time high
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.68 mean, 1=Strong Buy…5=Strong Sell) — 29 analysts
- Mean price target$276.59 range $200.00 – $328.00; median $280.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ABBV
- Consensus EPS estimate$3.84 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on continued successful discovery and clinical development of new drug candidates.","Significant exposure to potential patent challenges, generic/biosimilar competition, and legislative pricing pressures.","High leverage as reflected in the stockholders' deficit and debt levels."]
What changed in the latest 10-Q
AI-assisted comparison of ABBV's 10-Q filed 2026-05-08 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-08) covers Q1 2026 (three months ended March 31, 2026) whereas older filing (2025-11-04) covers Q3 2025 and nine months ended September 30, 2025
- Newer filing includes comparison period of three months ended March 31, 2025; older filing includes comparison periods of three months and nine months ended September 30, 2024
- Newer Balance Sheet in 2026 filing dated March 31, 2026 compared to December 31, 2025; older Balance Sheet dated September 30, 2025 compared to December 31, 2024
- Removed:
- Nine-month consolidated financial statements removed in newer filing; older filing presented both three-month and nine-month statements
- Short-term investments line item removed from current assets in newer Balance Sheet (was $42 million in older filing)
- Net foreign exchange loss (gain) line removed from newer earnings statement (was $20 million gain/loss in older filing)
- Other operating income line removed from newer earnings statement (was $(24)$ thousand in older filing)
- Finance lease obligations references removed from newer debt classifications; older filing referenced 'Current portion of long-term debt and finance lease obligations' and 'Long-term debt and finance lease obligations'
- Reworded:
- Balance Sheet liability line changed from 'Long-term debt and finance lease obligations' to 'Long-term debt' in newer filing
- Balance Sheet liability line changed from 'Current portion of long-term debt and finance lease obligations' to 'Current portion of long-term debt' in newer filing
- Income statement restructured to remove separate foreign exchange and other operating income line items; consolidated into 'Other expense, net' in newer filing
- Notes:
- The two filings report different periods (Q1 2026 vs Q3 2025) making direct financial comparisons not assessable as period-driven rather than accounting policy changes
- Partial truncation of cash flow statement in newer filing text may limit assessment completeness
- Balance sheet comparison periods differ (March 31, 2026 vs December 31, 2024 in older filing), driven by reporting cycle differences
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($8M) — 1 selling insider
- Last 90 days0 buys · 1 sell ($8M) — 1 selling insider
- Last 180 days0 buys · 1 sell ($8M) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-14. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ABBV's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 33 matched disclosures for ABBV from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding ABBV as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 257,497,691
- Reported value $56,003,172,616
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ABBV had 22,547,839 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ABBV had 1.28% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.98 days to cover at the same settlement.
- Reported short interest (shares) 22,547,839
- Short interest (% of shares outstanding) 1.28%
- Prior settlement (shares) 22,632,412
- Reported change -0.37%
- Days to cover (reported) 3.98
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Johnson & Johnson (JNJ)
- Pfizer (PFE)
- Bristol-Myers Squibb (BMY)
- Eli Lilly (LLY)
- Merck & Co. (MRK)
- Gilead Sciences (GILD)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ABBV vs…
AbbVie is found in…
ABBV ranks in…
ABBV shows up in…
Frequently asked questions
What does AbbVie (ABBV) do?
AbbVie is a research-based global biopharmaceutical company that develops and markets therapies for complex and serious diseases. Its product portfolio spans key therapeutic areas including immunology, oncology, neuroscience, eye care, and aesthetics. The company focuses on discovering and delivering innovative medicines that address significant unmet medical needs.
What sector is AbbVie (ABBV) in?
AbbVie (ABBV) is classified in the Health Care sector. Its industry is Biopharmaceuticals. It trades on NYSE.
Does ABBV pay a dividend?
Yes — AbbVie (ABBV) pays a dividend, with an indicated yield of about 4.47% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are AbbVie's (ABBV) competitors?
Notable peers of AbbVie (ABBV) include Amgen, Johnson & Johnson, Pfizer, Bristol-Myers Squibb and Eli Lilly. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in ABBV?
Yes — we hold 33 matched STOCK Act disclosures for ABBV from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is AbbVie (ABBV) overbought or oversold right now?
AbbVie (ABBV) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 64, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ABBV come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.